Category: Hematology
-
Daxor’s stock rises following FDA’s clearance for rapid blood volume analyzer
The company’s new hand-held system offers faster, more accurate patient fluid assessment at the point of care.
-
Novo Nordisk’s stock rises with broad US FDA approval for Alhemo
Alhemo wins FDA nod for hemophilia A and B without inhibitors, showing up to 86% fewer bleeds in a Phase III trial.
-
Regeneron’s Lynozyfic gains FDA accelerated approval for multiple myeloma
The approval puts the company’s bispecific antibody in a highly competitive space with the likes of J&J and Pfizer.
-
Enterome’s immunotherapy shows promising results in lymphoma trial
A 60% complete remission rate was seen with EO2463 in a Phase II trial in relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) patients.
-
Grifols gears up for launch of fibrogen therapy after publication of Phase III results
Grifols’ fibrinogen therapy BT524 set for EU launch in 2025, and potential US launch next year, after positive AdFIrst Phase III trial results.
-
Study finds patent tactics inflate drug prices, burden US patients
BMS and Pfizer’s Eliquis and Novo Nordisk’s semaglutide drugs cost US patients billions due to delayed generic access, I-MAK data shows.
-
AstraZeneca scoops up FibroGen’s China operations for $160 million
Along with FibroGen’s China subsidiary operations, AstraZeneca will acquire all rights to the anti-anemia medication, Evrenzo, in the country.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.